Bakouny Z, et al. - Authors examined the efficiency of anti-tumor necrosis factor (anti-TNF) agents in the prevention of postoperative endoscopic as well as the clinical recurrence of Crohn's disease (CD) after ileocolonic resection. They reported the following results for endoscopic recurrence as compared to infliximab: adalimumab [odds ratio (OR), 0.92; 95% confidence interval (CI), 0.18-4.75], thiopurines (OR, 4.11; 95% CI, 0.68-24.78), placebo (OR, 4.39; 95% CI, 0.70-27.68), and Mesalamine (OR, 37.84; 95% CI, 3.77-379.42). They also noted adalimumab (OR, 1.03; 95% CI, 0.17-6.03), thiopurines (OR, 1.40; 95% CI, 0.20-10.02), placebo (OR, 1.77; 95% CI, 1.01-3.10), and mesalamine (OR, 16.54; 95% CI, 1.55-176.24) for clinical recurrence. Overall, they suggested the utility of either adalimumab or infliximab in the postoperative prophylaxis of CD recurrence.